Ulcerative Colitis
First-line treatment with vedolizumab linked to fewer hospitalizations, surgeries in IBD
The treatment sequence of vedolizumab to adalimumab resulted in the lowest overall incidences of hospitalization and surgery in both Crohn’s disease and ulcerative colitis compared with other biologic treatment sequences, research showed.
Initial dose of infliximab 5 mg/kg ‘should be adequate’ in most cases of acute severe UC
No significant differences were reported in clinical response at day 7 between 5 mg/kg and 10 kg/kg doses of infliximab in acute severe ulcerative colitis, nor were there differences in intensified, accelerated or standard dosing at month 3.
After July surge, FDA approvals for GI settle into summer lull: What you may have missed
Following a July boom in game-changing FDA approvals for gastroenterology, including the first blood test for colorectal cancer, the agency has succumbed to the summer lull with only three approvals for GI to close out the season.
Tremfya nabs FDA approval for active ulcerative colitis, chasing competitor Skyrizi
The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of patients with moderately to severely active ulcerative colitis, according to a company release.
PBMs vs. patients: The hidden battle for affordable biosimilars
Biosimilar medications — drugs developed to be very similar, but not identical, to an FDA-approved biologic — were intended to play a vital role in increasing affordable options for patients struggling with a range of chronic conditions.
Filgotinib maintains remission, improves quality of life over 4 years in UC
Long-term filgotinib induced and maintained symptomatic remission and improved health-related quality of life in ulcerative colitis, with no new safety signals reported, according to interim analysis of the SELECTION extension study.